Company: HURA
Filing Date: 2025-09-18
Form Type: S-1/A
Source: 0001193125-25-207395
Chunk: 351

Company: TuHURA Biosciences, Inc./NV
Filing Date: 2025-09-18
Form: S-1/A
Chunk 351
---
 |   |        2,210,813 |   |
| Less accumulated depreciation and amortization |     |   |   (2,114,876 | ) |     |   |       (2,087,447 | ) |
|                                                |     | $ |      144,171 |   |     | $ |          123,366 |   |

Depreciation and amortization of property and equipment totaled approximately $ 14,000and $ 27,000for the three and six months ended June 30, 2025, and approximately $ 35,000and $ 70,000for the three and six months ended June 30 2024, respectively.

**Note 8-Accountspayable, debt, and accrued expenses**

Accounts payable and accrued expenses consist of the following as of June 30, 2025, and 2024:

|                                                                                         |     |   | June 30,2025 |     |   | December 31,2024 |
|:----------------------------------------------------------------------------------------|:----|:--|-------------:|:----|:--|-----------------:|
| Trade accounts payable                                                                  |     | $ |    3,646,806 |     | $ |        3,152,816 |
| Accrued compensation                                                                    |     |   |      809,237 |     |   |        1,161,650 |
| Assumed liabilities from Kineta merger (accounts payable and employee separation costs) |     |   |    5,211,727 |     |   |                — |
| Other accrued expenses                                                                  |     |   |    2,425,393 |     |   |          855,700 |
|                                                                                         |     | $ |   12,093,163 |     | $ |        5,170,166 |

As part of the acquisition of Kineta, the Company assumed debt with a fair value of $ 434,000and included under current liabilities on the Company’s Condensed Consolidated Balance Sheets as of June 30, 2025. The assumed debt was settled and paid in July 2025.

Note 9-Incometaxes Deferred tax assets and liabilities are determined based on the difference between the financial statement and tax bases of assets and liabilities using enacted tax rates in effect for the year in which the differences are expected to reverse. Valuation allowances are provided if based upon the weight of available evidence, it is more likely than not